All Stories

  1. Impact of obstructive sleep apnoea on cognitive function in multiple sclerosis: A longitudinal study
  2. The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis
  3. Slowed Luminance Reaction Times in Cervical Dystonia: Disordered Superior Colliculus Processing
  4. Temporal discrimination threshold and blink reflex recovery cycle in cervical dystonia – two sides of the same coin?
  5. A Study of the Midbrain Network for Covert Attentional Orienting in Cervical Dystonia Patients using Dynamic Causal Modelling
  6. Characterizing Brain Network Topology in Cervical Dystonia Patients and Unaffected Relatives via Graph Theory
  7. Neural Correlates of Abnormal Temporal Discrimination in Unaffected Relatives of Cervical Dystonia Patients
  8. Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia
  9. The premotor syndrome of cervical dystonia: Disordered processing of salient environmental stimuli
  10. PO089 Disrupted superior collicular activity may reveal cervical dystonia disease pathomechanisms
  11. Disrupted superior collicular activity may reveal cervical dystonia disease pathomechanisms
  12. Temporal Discrimination: Mechanisms and Relevance to Adult-Onset Dystonia
  13. Practice does not make perfect: Temporal discrimination in musicians with and without dystonia
  14. Marta Elian: Obituary
  15. Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland
  16. Integrated multidisciplinary clinics should be the gold standard in managing progressive MS – Commentary
  17. All relapsing multiple sclerosis patients should be managed at a specialist clinic – Commentary
  18. A useful annual review of cognition in relapsing MS is beyond most neurologists – Commentary
  19. Modeling the course and outcomes of MS is statistical twaddle—Commentary
  20. Neurodegeneration in multiple sclerosis is a process separate from inflammation: No
  21. THE MS-SMART TRIAL IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: A MULTI-ARM, MULTI-CENTRE TRIAL OF NEUROPROTECTION
  22. Multiple sclerosis relapse phenotype is an important, neglected determinant of disease-outcome: Commentary
  23. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary
  24. Young Women do it Better: Sexual Dimorphism in Temporal Discrimination
  25. Non-parametric bootstrapping method for measuring the temporal discrimination threshold for movement disorders
  26. Symptomatic therapy in multiple sclerosis: Big pharma should do more – commentary
  27. A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis
  28. The best clinical paper on multiple sclerosis in 2014: Herodotus and Chataway − Commentary
  29. Sun exposure is an environmental factor for the development of blepharospasm
  30. Unmet needs of multiple sclerosis patients in the community
  31. The best basic science paper in multiple sclerosis in 2014: Citicoline, remyelination and neuroprotection: Commentary
  32. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
  33. Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis - Commentary
  34. We can compare the relative efficacy multiple sclerosis medications by examining the results of independent clinical trials: Commentary
  35. Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM
  36. Efficacy of delayed‐release dimethyl fumarate in relapsing‐remitting multiple sclerosis: integrated analysis of the phase 3 trials
  37. The best basic science paper in multiple sclerosis in 2013: Disease specific molecular events in cortical multiple sclerosis lesions
  38. Economic costs associated with an MS relapse
  39. Spinal cord MRI should always be performed in clinically isolated syndrome patients: Commentary
  40. Multiparity in women with multiple sclerosis causes less long-term disability: Commentary
  41. Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Commentary
  42. Epidemiology of Wilson's disease in Ireland
  43. Electrophysiological and behavioral measures of visuo-motor learning for application in movement disorders
  44. Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: Commentary
  45. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel
  46. An evaluation of the role of environmental factors in the disease penetrance of cervical dystonia
  47. The best clinical paper of 2013: Commentary
  48. Cervical Dystonia: A Disorder of the Midbrain Network for Covert Attentional Orienting
  49. Dexterity Training Improves Manual Precision in Patients Affected by Essential Tremor
  50. MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: Commentary
  51. Temporal discrimination, a cervical dystonia endophenotype: Penetrance and functional correlates
  52. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison
  53. Evoked potentials are of little use in the diagnosis or monitoring of MS: Commentary
  54. Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: Commentary
  55. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study
  56. The endophenotype and the phenotype: Temporal discrimination and adult-onset dystonia
  57. DOES JCV ANTIBODY POSITIVITY ENCOURAGE CESSATION OF NATALIZUMAB THERAPY IN MULTIPLE SCLEROSIS?
  58. Longitudinal assessment of the multiple sclerosis impact scale (MSIS-29) amongst A treated relapsing remitting multiple sclerosis cohort
  59. One can prevent post-partum MS relapses by exclusive breast feeding: Commentary
  60. Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM
  61. The best basic science paper on multiple sclerosis in 2012: Commentary
  62. Pallidal stimulation for cervical dystonia does not correct abnormal temporal discrimination
  63. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study
  64. Funding CCSVI research is/was a waste of valuable time, money and intellectual energy: Commentary
  65. A novelCACNA1Amutation associated with adult-onset, paroxysmal head tremor
  66. CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald Criteria 2010: Commentary
  67. The best clinical paper on multiple sclerosis in 2012: Commentary
  68. Symptom overlap in anxiety and multiple sclerosis
  69. If I had CIS with MRI diagnostic of MS, I would take vitamin D 10,000 IU daily: Commentary
  70. Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double- blind placebo-controlled trial
  71. In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: Commentary
  72. The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: Commentary
  73. A proposed modification to the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis
  74. AGE-RELATED PENETRANCE OF ABNORMAL TEMPORAL DISCRIMINATION THRESHOLDS IN UNAFFECTED FIRST-DEGREE RELATIVES OF ADULT ONSET PRIMARY TORSION DYSTONIA PATIENTS
  75. THE COST OF A MULTIPLE SCLEROSIS RELAPSE
  76. Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time: Commentary
  77. Rehabilitation therapy in MS: a short-term, expensive, placebo: Commentary
  78. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
  79. Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: Commentary
  80. Does natalizumab therapy worsen neuromyelitis optica?
  81. Response to comment on the article by Allen et al. ‘A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers’
  82. Deaths and disability from natalizumab are no longer tolerable: Commentary
  83. Current Treatments for Progressive Multiple Sclerosis: Disease-Modifying Therapies
  84. There is no such thing as a mild MS relapse. The mild relapse is an Anglo-Saxon delusion - Commentary
  85. We are about to cure MS in the next 10 years, even though we do not know its cause: Commentary
  86. The neurologist’s dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately – Commentary
  87. Penetrance of Abnormal Temporal Discrimination Thresholds in Unaffected First-Degree Relatives of Adult Onset Primary Torsion Dystonia Patients (P01.218)
  88. Functional Correlates of Temporal Discrimination in Adult Onset Primary Torsion Dystonia Patients and Unaffected First-Degree Relatives (P01.220)
  89. The Importance of CSF Oligoclonal Bands in the Diagnosis of Primary Progressive Multiple Sclerosis (P01.139)
  90. Relapsing Anti-Glycine Receptor Antibody Mediated Encephalitis with Rigidity and Myoclonus (P01.235)
  91. Do not treat from CIS onset: evaluate disease course and prognosis first - Commentary
  92. A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers
  93. In assessing multiple sclerosis disease activity patient report measures are a waste of time: cut to the MRI scan! – Commentary
  94. 1612 Sporadic AOPTD is a genetic disorder: evidence from the temporal discrimination threshold
  95. 122 Functional correlates of abnormal temporal discrimination in adult onset primary torsion dystonia patients and first-degree relatives
  96. 136 Initial experience of alemtuzumab for patients who fail natalizumab therapy
  97. 040 Electronic neurology referrals: a solution for an overburdened healthcare system?
  98. 0854 The sensitivity of JC virus DNA detection vs JC virus antibody testing in a natalizumab-treated group of relapsing MS patients
  99. Epidemiology of multiple sclerosis has had its day: there are no more unanswered questions - Commentary
  100. Truly benign multiple sclerosis is rare: let’s stop fooling ourselves - Commentary
  101. Relapses do not matter in relation to long-term disability: Commentary
  102. A budget impact analysis of natalizumab use in Ireland
  103. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS
  104. Spontaneous intracranial hypotension: case reports and literature review
  105. The major cause of multiple sclerosis is environmental: genetics has a minor role - Commentary
  106. Controversies in multiple sclerosis: a series of debates
  107. Translation Initiator EIF4G1 Mutations in Familial Parkinson Disease
  108. Using atypical symptoms and red flags to identify non-demyelinating disease
  109. Sporadic adult onset primary torsion dystonia is a genetic disorder by the temporal discrimination test
  110. Temporal discrimination thresholds in adult-onset primary torsion dystonia: an analysis by task type and by dystonia phenotype
  111. Change in PASAT performance correlates with change in P3 ERP amplitude over a 12-month period in multiple sclerosis patients
  112. Preliminary evidence for correlation between PASAT performance and P3a and P3b amplitudes in progressive multiple sclerosis
  113. Multiple sclerosis, from referral to confirmed diagnosis: an audit of clinical practice
  114. Safety first, efficacy second in disease modifying therapies
  115. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
  116. Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype
  117. ‘Switching off’ SUNCT by sudden head movement: a new symptom
  118. POMD04 Utility of temporal discrimination threshold testing in different adult-onset primary torsion dystonia phenotypes
  119. POMD05 Temporal discrimination threshold in patients with sporadic adult-onset primary torsion dystonia and their first degree relatives
  120. POMD06 Utility of visual, tactile and mixed tasks in the determination of temporal discrimination thresholds in adult-onset primary torsion dystonia
  121. POI09 Trends in BK and JC polyomavirus and relationship to CD4+/CD8+ ratio in patients with relapsing remitting multiple sclerosis on natalizumab therapy
  122. POI10 Using atypical symptoms to predict nondemyelinating disease in patients as "query multiple sclerosis"
  123. Natalizumab Therapy of Multiple Sclerosis
  124. A high-density ERP study reveals latency, amplitude, and topographical differences in multiple sclerosis patients versus controls☆
  125. OAS1: A multiple sclerosis susceptibility gene that influences disease severity
  126. New perspectives in the natural history of multiple sclerosis
  127. Impaired information processing speed and attention allocation in multiple sclerosis patients versus controls: A high-density EEG study
  128. Obituary
  129. Clinically isolated syndrome: a protected zone for trials of new therapies?
  130. Patient-centered outcomes: Translating clinical efficacy into benefits on health-related quality of life
  131. Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?
  132. Comparing endophenotypes in adult-onset primary torsion dystonia
  133. Sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO) in a sibling pair with a homozygous p.A467T POLG mutation
  134. Natalizumab therapy of multiple sclerosis
  135. Clinical Reasoning: An unusual case of papilledema after orthotopic liver transplantation
  136. Dementia in SPG4 hereditary spastic paraplegia: Clinical, genetic, and neuropathologic evidence
  137. Assessing disability progression with the Multiple Sclerosis Functional Composite
  138. Genetic polymorphisms, their allele combinations and IFN-β treatment response in Irish multiple sclerosis patients
  139. Temporal Discrimination Threshold: VBM evidence for an endophenotype in adult onset primary torsion dystonia
  140. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia
  141. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
  142. Predicting and preventing the future: actively managing multiple sclerosis
  143. Striatal morphology correlates with sensory abnormalities in unaffected relatives of cervical dystonia patients
  144. Tolosa-Hunt syndrome responsive to infliximab therapy
  145. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
  146. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
  147. Fluctuations in T helper subpopulations in relapsing-remitting multiple sclerosis
  148. Clinical correlates of abnormal brain-stem auditory evoked responses in multiple sclerosis
  149. CSF myelin basic protein in multiple sclerosis
  150. Clinical Reasoning: A case of Wegener granulomatosis complicated by seizures and headaches: Curiouser and curiouser
  151. Reactivation of BK polyomavirus in patients with multiple sclerosis receiving natalizumab therapy
  152. Cervical dystonia presenting as a phenocopy in an Irish SCA2 family
  153. Counting the cost of complementary and alternative therapies in an Irish neurological clinic
  154. PROGRESSIVE ENCEPHALOMYELITIS, RIGIDITY, AND MYOCLONUS: A NOVEL GLYCINE RECEPTOR ANTIBODY
  155. Differential diagnosis of suspected multiple sclerosis: a consensus approach
  156. New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin
  157. Intravenous therapy for the treatment of multiple sclerosis
  158. Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease
  159. REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31
  160. Unusual MRI abnormalities in anti-Yo positive "pure" paraneoplastic cerebellar degeneration
  161. Molding the sensory cortex: Spatial acuity improves after botulinum toxin treatment for cervical dystonia
  162. The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite
  163. Sporadic adult onset dystonia: sensory abnormalities as an endophenotype in unaffected relatives
  164. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL
  165. Health-related quality of life in multiple sclerosis: effects of natalizumab
  166. Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis
  167. The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical)
  168. Is a 20% change in MSFC components clinically meaningful?
  169. What difference does a neurologist make in a general hospital? Estimating the impact of neurology consultations on in-patient care
  170. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
  171. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis
  172. Natalizumab: A new treatment for relapsing remitting multiple sclerosis
  173. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis
  174. Linkage to a known gene but no mutation identified: comprehensive reanalysis ofSPG4 HSP pedigrees reveals large deletions as the sole cause
  175. Paroxysmal torticollis and blepharospasm following bilateral cerebellar Infarction
  176. FC46.3 Assessment of intracortical inhibition in familial adult-onset dystonia using paired transcranial magnetic stimulation
  177. Human leucocyte antigen class II polymorphism in Irish patients with multiple sclerosis
  178. The Face-Symbol Test and the Symbol-Digit Test are not reliable surrogates for the Paced Auditory Serial Addition Test in multiple sclerosis
  179. Hereditary spastic paraparesis and psychosis
  180. Mapping candidate non-MHC susceptibility regions to multiple sclerosis
  181. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
  182. Unrecognised symptoms of depression in a community–based population with multiple sclerosis
  183. Sensory abnormalities in unaffected relatives in familial adult-onset dystonia
  184. Population frequency of HLA haplotypes contributes to the prevalence difference of multiple sclerosis in Ireland
  185. Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy
  186. Fatal toxic leukoencephalopathy: clinical, radiological, and necropsy findings in two patients
  187. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns
  188. Inherited myoclonus-dystonia and epilepsy: Further evidence of an association?
  189. Age at onset as a factor in determining the phenotype of primary torsion dystonia
  190. Transition from paediatric to adult neurological services * Authors' reply
  191. Familial adolescent-onset scoliosis and later segmental dystonia in an Irish family
  192. Confirming the validity and responsiveness of the Multiple Sclerosis Walking Scale-12 (MSWS-12)
  193. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse
  194. Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity
  195. Further evidence of dementia in SPG4-linked autosomal dominant hereditary spastic paraplegia
  196. Cervical dystonia following peripheral trauma
  197. Creutzfeldt-Jakob Disease in Ireland: Epidemiological Aspects 1980–2002
  198. Progressive multifocal leucoencephalopathy presenting with Parkinsonism
  199. A genome wide scan for association with multiple sclerosis in a N. Irish case control population
  200. Case report: Recurrent temporalis muscle swelling and headache
  201. Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities
  202. CADASIL imitating multiple sclerosis: the importance of MRI markers
  203. Leigh disease associated with a novel mitochondrial DNA ND5 mutation
  204. Primary torsion dystonia due to the TOR1A GAG deletion in an Irish family
  205. The prevalence of "pure" autosomal dominant hereditary spastic paraparesis in the island of Ireland
  206. Interferon- 1b in the treatment of secondary progressive MS: Impact on quality of life
  207. SPG15, a new locus for autosomal recessive complicated HSP on chromosome 14q
  208. Hemichorea, moya-moya, and ulcerative colitis
  209. Phenotype of AD-HSP due to mutations in the SPAST gene: Comparison with AD-HSP without mutations
  210. Ocular microtremor (OMT): a new neurophysiological approach to multiple sclerosis
  211. Age-related cognitive decline in hereditary spastic paraparesis linked to chromosome 2p
  212. Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia
  213. Amnesic syndrome with bilateral mesial temporal lobe involvement in Hashimoto's encephalopathy
  214. Recurrent optic disc edema with a macular star (ODEMS)
  215. A family with pseudodominant Friedreich's ataxia showing marked variation of phenotype between affected siblings
  216. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases
  217. Transient global amnesia: 'amnesia by the seaside' revisited
  218. Mutation of the acetylcholine receptor ɛ‐subunit promoter in congenital myasthenic syndrome
  219. Rate of Pregnancy-Related Relapse in Multiple Sclerosis
  220. Giant cell arteritis presenting as lateral medullary syndrome
  221. The incidence of sudden unexpected death in epilepsy (sudep) in south dublin and wicklow
  222. Rate of Pregnancy-Related Relapse in Multiple Sclerosis
  223. Linkage of AD HSP and cognitive impairment to chromosome 2p: haplotype and phenotype analysis indicates variable expression and low or delayed penetrance
  224. Cognitive impairment in families with pure autosomal dominant hereditary spastic paraparesis
  225. Autosomal dominant hereditary spastic paraparesis with cognitive loss linked to chromosome 2p
  226. Two families with autosomal recessive spastic paraplegia, pigmented maculopathy, and dementia
  227. Cranial and peripheral neuropathy due to Epstein-Barr virus infection.
  228. A Family with Hereditary Spastic Paraparesis and Epilepsy
  229. Superficial siderosis of the central nervous system
  230. Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL)
  231. Do Alpha-Blockers Have a Role in Lower Urinary Tract Dysfunction in Multiple Sclerosis?
  232. Do Alpha-Blockers Have a Role in Lower Urinary Tract Dysfunction in Multiple Sclerosis?
  233. Neuroleptic malignant syndrome.
  234. The functional limitations profile may be a valid, reliable and sensitive measure of disability in multiple sclerosis
  235. The influence of pregnancy on multiple sclerosis: a European multicentric prospective study — First results
  236. Amnesic syndrome after theophylline associated seizures: iatrogenic brain injury.
  237. Worsening of myasthenia gravis on treatment with imipenem/cilastatin.
  238. Bipolar affective disorder prior to the onset of multiple sclerosis
  239. Pregnancy in multiple sclerosis.
  240. Psychosis and multiple sclerosis
  241. An epidemiological study of Wilson's disease in the Republic of Ireland.
  242. Plantar power: reproducibility of the plantar response.
  243. Suxamethonium is contraindicated in the Guillain-Barre syndrome.
  244. Livedo reticularis and dementia
  245. Irish Neurological association
  246. Progressive multifocal leukoencephalopathy-remission with cytarabine
  247. Benign recurrent multiple mononeuropathy in Wegener's granulomatosis.
  248. Contrast sensitivity in multiple sclerosis measured by Cambridge Low Contrast Gratings: a useful clinical test?
  249. Chronic hypothermia in multiple sclerosis.
  250. Three possible laboratory indexes of disease activity in multiple sclerosis
  251. Peripheral blood T lymphocyte changes in multiple sclerosis: a marker of disease progression rather than of relapse?
  252. Late responses as aids to diagnosis in peripheral neuropathy.
  253. Royal academy of medicine in Ireland section of medicine
  254. Oligoclonal bands in multiple sclerosis: An index of disease activity?
  255. Suspected and clinically definite multiple sclerosis: the relationship between CSF immunoglobulins and clinical course.
  256. Suppressor T cell changes in active multiple sclerosis: analysis with three different monoclonal antibodies.
  257. Irish neurological association
  258. Visual evoked responses and immunoglobulin abnormalities in the diagnosis of multiple sclerosis
  259. Neurological lupus erythematosus with tonic seizures simulating multiple sclerosis.
  260. Papilledema in two patients with acromegaly and intrasellar pituitary tumors
  261. GENERAL DISEASE IN 120 NECROPSY-PROVEN CASES OF MULTIPLE SCLEROSIS
  262. Acute optic neuritis and the prognosis for multiple sclerosis.
  263. Measles-virus-specific IgG in optic neuritis and in multiple sclerosis after optic neuritis.